Literature DB >> 27091031

Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice.

Jérôme Bouligand1,2, Clémentine Richard1,2,3, Dominique Valteau-Couanet4, Cedric Orear5, Lionel Mercier3, Romain Kessari6,7,8, Nicolas Simonnard6,7,8, Fabienne Munier6,7,8, Estelle Daudigeos-Dubus6,7,8, Bassim Tou1,2, Paule Opolon6,7,8, Alain Deroussent6,7,8, Angelo Paci9,10,11,12,13, Gilles Vassal6,7,8,14.   

Abstract

PURPOSE: Busulfan-melphalan high-dose chemotherapy followed by autologous stem cell transplantation is an essential consolidation treatment of high-risk neuroblastoma in children. Main treatment limitation is hepatic veno-occlusive disease, the most severe and frequent extra-hematological toxicity. This life threatening toxicity has been related to a drug interaction between busulfan and melphalan which might be increased by prior disturbance of iron homeostasis, i.e. an increased plasma ferritin level.
METHODS: We performed an experimental study of busulfan and melphalan pharmacodynamic and pharmacokinetics in iron overloaded mice.
RESULTS: Iron excess dramatically increased the toxicity of melphalan or busulfan melphalan combination in mice but it did not modify the clearance of either busulfan or melphalan. We show that prior busulfan treatment impairs the clearance of melphalan. This clearance alteration was exacerbated in iron overloaded mice demonstrating a pharmacokinetic interaction. Additionally, iron overload increased melphalan toxicity without altering its pharmacokinetics, suggesting a pharmacodynamic interaction between iron and melphalan. Based on iron homeostasis disturbance, we postulated that prior induction of ferritin, through Nrf2 activation after oxidative stress, may be associated with the alteration of melphalan metabolism.
CONCLUSION: Iron overload increases melphalan and busulfan-melphalan toxicity through a pharmacodynamic interaction and reveals a pharmacokinetic drug interaction between busulfan and melphalan.

Entities:  

Keywords:  Nrf2; bone marrow transplantation; drug interaction; glutathione; metabolism; mice; pharmacodynamic; pharmacokinetics; toxicity

Mesh:

Substances:

Year:  2016        PMID: 27091031     DOI: 10.1007/s11095-016-1927-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.

Authors:  Angelo Paci; Gilles Vassal; Despina Moshous; Jean-Hugues Dalle; Nathalie Bleyzac; Bénédicte Neven; Claire Galambrun; Véronique Kemmel; Zeinab D Abdi; Sophie Broutin; Aurélie Pétain; Laurent Nguyen
Journal:  Ther Drug Monit       Date:  2012-04       Impact factor: 3.681

2.  Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?

Authors:  G Vassal; A Deroussent; D Challine; O Hartmann; S Koscielny; D Valteau-Couanet; J Lemerle; A Gouyette
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

3.  Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity.

Authors:  L I Gordon; S G Brown; M S Tallman; A W Rademaker; S A Weitzman; H M Lazarus; C H Kelley; C Mangan; H Rubin; R M Fox
Journal:  Free Radic Biol Med       Date:  1995-03       Impact factor: 7.376

4.  The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.

Authors:  A R Kallianpur; L D Hall; M Yadav; D W Byrne; T Speroff; R S Dittus; J L Haines; B W Christman; M L Summar
Journal:  Bone Marrow Transplant       Date:  2005-06       Impact factor: 5.483

5.  Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury.

Authors:  Jacqui M Marzec; Jason D Christie; Sekhar P Reddy; Anne E Jedlicka; Hue Vuong; Paul N Lanken; Richard Aplenc; Tae Yamamoto; Masayuki Yamamoto; Hye-Youn Cho; Steven R Kleeberger
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

6.  Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.

Authors:  J Bouligand; O Cabaret; M Canonico; C Verstuyft; L Dubert; L Becquemont; A Guiochon-Mantel; P Y Scarabin
Journal:  Clin Pharmacol Ther       Date:  2010-11-24       Impact factor: 6.875

7.  Familial glucocorticoid receptor haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  Jérôme Bouligand; Brigitte Delemer; Annie-Claude Hecart; Geri Meduri; Say Viengchareun; Larbi Amazit; Séverine Trabado; Bruno Fève; Anne Guiochon-Mantel; Jacques Young; Marc Lombès
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

8.  Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.

Authors:  A Cacchione; A LeMaitre; D Valteau Couanet; E Benhamou; L Amoroso; N Simonnard; O Hartmann
Journal:  Bone Marrow Transplant       Date:  2008-06-30       Impact factor: 5.483

Review 9.  Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress.

Authors:  A M Evens; J Mehta; L I Gordon
Journal:  Bone Marrow Transplant       Date:  2004-10       Impact factor: 5.483

10.  Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.

Authors:  J Bouligand; A Le Maitre; D Valteau-Couanet; J Grill; L Drouard-Troalen; A Paci; O Hartmann; E Benhamou; G Vassal
Journal:  Clin Pharmacol Ther       Date:  2007-03-28       Impact factor: 6.875

View more
  4 in total

Review 1.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

Review 2.  Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.

Authors:  Erden Atilla; Selami K Toprak; Taner Demirer
Journal:  Turk J Haematol       Date:  2016-12-12       Impact factor: 1.831

3.  NRF2 -617 C/A Polymorphism Impacts Proinflammatory Cytokine Levels, Survival, and Transplant-Related Mortality After Hematopoietic Stem Cell Transplantation in Adult Patients Receiving Busulfan-Based Conditioning Regimens.

Authors:  Jingjing Huang; Chenxia Hao; Ziwei Li; Ling Wang; Jieling Jiang; Wei Tang; Lining Wang; Weixia Zhang; Jiong Hu; Wanhua Yang
Journal:  Front Pharmacol       Date:  2020-12-15       Impact factor: 5.810

4.  Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan.

Authors:  Rong-Long Chen; Li-Hua Fang; Xin-Yi Yang; Mohsin El Amrani; Esther Veronique Uijtendaal; Yen-Fu Chen; Wei-Chi Ku
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.